0001104659-23-036691.txt : 20230324 0001104659-23-036691.hdr.sgml : 20230324 20230324171018 ACCESSION NUMBER: 0001104659-23-036691 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230320 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230324 DATE AS OF CHANGE: 20230324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medicine Man Technologies, Inc. CENTRAL INDEX KEY: 0001622879 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 465289499 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55450 FILM NUMBER: 23760722 BUSINESS ADDRESS: STREET 1: 4880 HAVANA STREET STREET 2: SUITE 201 SOUTH CITY: DENVER STATE: CO ZIP: 80239 BUSINESS PHONE: 303-371-0387 MAIL ADDRESS: STREET 1: 4880 HAVANA STREET STREET 2: SUITE 201 SOUTH CITY: DENVER STATE: CO ZIP: 80239 8-K 1 tm2310513d1_8k.htm FORM 8-K
0001622879 false 0001622879 2023-03-20 2023-03-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 20, 2023

 

Medicine Man Technologies, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada 000-55450 46-5289499
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

 

4880 Havana Street, Suite 201

Denver, Colorado

  80239
(Address of Principal Executive Offices)   (Zip Code)
     
(303) 371-0387
(Registrant’s Telephone Number, Including Area Code)
     
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange On Which
Registered
Not applicable   Not applicable   Not applicable

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨                 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 20, 2023, Medicine Man Technologies, Inc. (the “Company”) received notice of the resignation of Salim Wahdan as a member of the Company’s board of directors (the “Board”), to be effective upon the Board’s nomination and appointment of another director to fill his vacancy. Mr. Wahdan was not a member of any committees of the Board. Mr. Wahdan’s resignation is not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies, or practices.

 

On March 23, 2023, the Board appointed Bradley Stewart as a Class A director to fill the vacancy left by Mr. Wahdan. The Company expects that the Board will appoint Mr. Stewart to one or more of the committees of the Board; however, no committee appointments have been determined at this time. Mr. Stewart will serve until his term expires at the Company’s 2024 annual meeting of stockholders and until a successor is elected and qualified, or until his earlier death, resignation or removal.

 

Currently, Mr. Stewart serves as Chairman of Perch, a technology driven e-commerce company, and a Senior Advisor with Sixth Street Partners, a private equity fund. Mr. Stewart also serves as an independent director for Private Medical, a privately-held company, and Semper Paratus, a Nasdaq listed company. Prior to his current roles, Mr. Stewart served as Chief Executive Officer and a director of Fair Technologies, an automobile leasing company. Between 2010 and 2019, Mr. Stewart held several positions at Xojet, an on-demand private jet company, starting as an advisor and departing from the company as Chief Executive Officer and Chairman of the board of directors. Mr. Stewart received his MBA from Columbia Business School and his Bachelor of Science in Business at the University of Minnesota.

 

Mr. Stewart was designated for appointment to the Board as the joint designee of Brian Ruden and Naser Joudeh pursuant to the Omnibus Amendment No. 2 to Asset Purchase Agreements, dated December 17, 2020, among the Company and the sellers party thereto (the “Omnibus Amendment”). Between December 17, 2020 and March 2, 2021, the Company’s wholly-owned subsidiary, SBUD LLC, acquired the assets of a number of Star Buds retail dispensaries located in Colorado. The Omnibus Amendment provides that, for as long as the Sellers (as defined in the Omnibus Amendment) and the Members (as defined in the Omnibus Amendment) meet a specified ownership threshold, the Company shall recommend to the Board that Brian Ruden and Naser Joudeh jointly be permitted to designate three directors for appointment to the Board if the Board consists of seven or more members. Currently, Pratap Mukharji, Marc Rubin, and Brad Stewart serve as Messrs. Ruden and Joudeh’s designees on the Board. The Company previously reported the terms of the Omnibus Amendment in the Company’s Current Report on Form 8-K filed on December 23, 2020 and attached a copy of the Omnibus Amendment as Exhibit 2.1 thereto, and such disclosure and exhibit are incorporated by reference herein.

 

The Company’s current director compensation policy is to award each non-executive director (i) an annual grant of shares of the Company’s common stock worth $70,000 and (ii) an annual award of $35,000, payable in cash or shares of the Company’s common stock at the option of the recipient director. The Company expects to make such awards to Mr. Stewart in the future, but no awards have been granted as of the date of this report.

 

Item 7.01 Regulation FD Disclosure.

 

On March 24, 2023, the Company issued a press release announcing the appointment of Brad Stewart to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

The information under Item 7.01 of this Current Report on Form 8-K and the press release attached as Exhibit 99.1 are being furnished by the Company pursuant to Item 7.01. In accordance with General Instruction B.2 of Form 8-K, the information under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. In addition, this information shall not be deemed incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in any such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No. Description
99.1 Press Release, dated March 24, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MEDICINE MAN TECHNOLOGIES, INC.
   
  By:  /s/ Daniel R. Pabon
Date:  March 24, 2023   Daniel R. Pabon
    General Counsel

 

 

 

 EX-99.1 2 tm2310513d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

NEWS RELEASE OTCQX: SHWZ
For Immediate Release NEO: SHWZ

 

SCHWAZZE ANNOUNCES APPOINTMENT TO THE BOARD OF DIRECTORS

 

DENVER, CO – March 24, 2023 – Medicine Man Technologies Inc. operating as Schwazze, (OTCQX:SHWZ; NEO:SHWZ) ("Schwazze" or the “Company"), today announced the appointment of Mr. Bradley Stewart to the Board of Directors of Schwazze. The Company also reports that Mr. Sal Wahdan has resigned as a Director of Schwazze.

 

Mr. Stewart is a Private Equity-backed CEO, board member and advisor, where he specializes in building technology and services companies with a focus on strategic transformation, balance sheet restructuring and M&A. He currently, serves as Senior Advisor at Sixth Street, as Chairman at Perch and as an independent board member at Private Medical and Semper Paratus (Nasdaq: LGSTU).

 

Previously, Mr. Stewart was CEO at Fair Technologies, a fintech / marketplace backed by SoftBank Group. Prior to Fair, he was Chairman and CEO at XOJet, the largest on-demand private jet services company in North America, backed by TPG and Mubadala, where he led the company’s turnaround. In concurrence with XOJet, he was a Senior Advisor at TPG, a leading private equity firm, where he served on the board of directors for multiple TPG portfolio companies. Prior to his tenure at XOJet and TPG, he was a Vice President at Parthenon Capital, a leading mid-market private equity firm, and formerly an Engagement Manager at McKinsey & Company. He received an MBA from Columbia Business School, a BSB in Corporate Finance from the University of Minnesota’s Carlson School of Management and a Lower Division Completion Certificate from the University of Minnesota's College of Science & Engineering.

 

Justin Dye, CEO of Schwazze stated, “We look forward to Brad’s participation on the Board of Directors of Schwazze as his strong experience and skills will be an excellent addition to our Board and the Company. We also would like to thank Sal for his valuable contributions to the Board and wish him well in his future endeavours.”

 

About Schwazze

Schwazze (OTCQX: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high- performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company's leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices. Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

 

 

 

 

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “plan,” “will,” “may,” “continue,” “predicts,” or similar words. Forward-looking statements include the guidance provided regarding the Company’s Q4 2022 performance and annual capital spending. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses and realize synergies therefrom, (ix) the ongoing COVID-19 pandemic, (x) the timing and extent of governmental stimulus programs, (xi) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws, and (xii) our ability to achieve the target metrics, including our annualized revenue and EBIDTA run rates set out in our Q4 2022 guidance. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

 

Investors

Joanne Jobin

Investor Relations

Joanne.jobin@schwazze.com

647 964 0292
Christine Jones
Chief Legal Counsel
Christine.Jones@schwazze.com
303 809 2697

Media

Julie Suntrup, Schwazze

Vice President | Marketing & Merchandising

julie.suntrup@schwazze.com

303 371 0387

 

2

 

 EX-101.SCH 3 shwz-20230320.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 shwz-20230320_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 shwz-20230320_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2310513d1_ex99-1img001.jpg GRAPHIC begin 644 tm2310513d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Mar. 20, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 20, 2023
Entity File Number 000-55450
Entity Registrant Name Medicine Man Technologies, Inc.
Entity Central Index Key 0001622879
Entity Tax Identification Number 46-5289499
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 4880 Havana Street
Entity Address, Address Line Two Suite 201
Entity Address, City or Town Denver
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80239
City Area Code 303
Local Phone Number 371-0387
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 8 tm2310513d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001622879 2023-03-20 2023-03-20 iso4217:USD shares iso4217:USD shares 0001622879 false 8-K 2023-03-20 Medicine Man Technologies, Inc. NV 000-55450 46-5289499 4880 Havana Street Suite 201 Denver CO 80239 303 371-0387 false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://medicinemantechnologies.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2310513d1_8k.htm shwz-20230320.xsd shwz-20230320_lab.xml shwz-20230320_pre.xml tm2310513d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2310513d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 20 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2310513d1_8k.htm" ] }, "labelLink": { "local": [ "shwz-20230320_lab.xml" ] }, "presentationLink": { "local": [ "shwz-20230320_pre.xml" ] }, "schema": { "local": [ "shwz-20230320.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "SHWZ", "nsuri": "http://medicinemantechnologies.com/20230320", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2310513d1_8k.htm", "contextRef": "From2023-03-20to2023-03-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://medicinemantechnologies.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2310513d1_8k.htm", "contextRef": "From2023-03-20to2023-03-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medicinemantechnologies.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-036691-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-036691-xbrl.zip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end